Search Result

Results for "

phosphodiesterase (PDE) inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Phosphodiesterase (PDE) (230) 5-HT Receptor (1) Adenosine Deaminase (2) Adenosine Receptor (7) Adrenergic Receptor (2) Apoptosis (23) Autophagy (8) Bacterial (5) Beta-secretase (1) Calcium Channel (7) Calmodulin (1) Cholinesterase (ChE) (1) Dopamine Receptor (1) Drug Metabolite (1) Endogenous Metabolite (15) GABA Receptor (1) Glucocorticoid Receptor (2) GPR35 (1) GSK-3 (2) HDAC (7) Histamine Receptor (2) HIV (4) IKK (2) Influenza Virus (3) Interleukin Related (5) JAK (1) mAChR (3) MAPKAPK2 (MK2) (1) MMP (1) Na+/H+ Exchanger (NHE) (1) NF-κB (2) NO Synthase (5) Nuclear Factor of activated T Cells (NFAT) (1) Parasite (2) PKA (7) Potassium Channel (2) Sodium Channel (2) TNF Receptor (8) Wnt (2) β-catenin (2)
By Research Areas:	Cancer (57) Cardiovascular Disease (63) Endocrinology (22) Infection (11) Inflammation/Immunology (80) Metabolic Disease (22) Neurological Disease (73)

By Targets:

Phosphodiesterase (PDE) (230)

5-HT Receptor (1)

Adenosine Deaminase (2)

Adenosine Receptor (7)

Adrenergic Receptor (2)

Apoptosis (23)

Autophagy (8)

Bacterial (5)

Beta-secretase (1)

Calcium Channel (7)

Calmodulin (1)

Cholinesterase (ChE) (1)

Dopamine Receptor (1)

Drug Metabolite (1)

Endogenous Metabolite (15)

GABA Receptor (1)

Glucocorticoid Receptor (2)

GPR35 (1)

GSK-3 (2)

HDAC (7)

Histamine Receptor (2)

HIV (4)

IKK (2)

Influenza Virus (3)

Interleukin Related (5)

JAK (1)

mAChR (3)

MAPKAPK2 (MK2) (1)

MMP (1)

Na+/H+ Exchanger (NHE) (1)

NF-κB (2)

NO Synthase (5)

Nuclear Factor of activated T Cells (NFAT) (1)

Parasite (2)

PKA (7)

Potassium Channel (2)

Sodium Channel (2)

TNF Receptor (8)

Wnt (2)

β-catenin (2)

By Research Areas:

Cancer (57)

Cardiovascular Disease (63)

Endocrinology (22)

Infection (11)

Inflammation/Immunology (80)

Metabolic Disease (22)

Neurological Disease (73)

241

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Targets Recommended: Phosphodiesterase (PDE)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0312

Dipyridamole 4 Publications Verification	Phosphodiesterase (PDE) Apoptosis	Cardiovascular Disease Cancer
Dipyridamole is an orally active phosphodiesterase (PDE) inhibitor. Dipyridamole also is an antiplatelet agent used in secondary prophylaxis against stroke. Dipyridamole can induce cancer cell-specific apoptosis .

HY-126137

PDE9-IN-1	Phosphodiesterase (PDE)	Neurological Disease
PDE9-IN-1 is a potent, selective, and orally bioavailable **phosphodiesterase-9A (PDE9A)** Inhibitor with an IC₅₀ of 8.7 nM .

HY-U00427

PDE2/PDE10-IN-1	Phosphodiesterase (PDE)	Neurological Disease
PDE2/PDE10-IN-1 is a phosphodiesterase 2 (PDE2) and *PDE10* inhibitor with IC₅₀s of 29 and 480 nM, respectively.

HY-B0312R

Dipyridamole (Standard)	Phosphodiesterase (PDE) Apoptosis	Cardiovascular Disease Cancer
Dipyridamole (Standard) is the analytical standard of Dipyridamole. This product is intended for research and analytical applications. Dipyridamole is an orally active phosphodiesterase (PDE) inhibitor. Dipyridamole also is an antiplatelet agent used in secondary prophylaxis against stroke. Dipyridamole can induce cancer cell-specific apoptosis .

HY-120684

PDE10-IN-6	Others	Others
PDE10-IN-6 is a phosphodiesterase-10 inhibitor that inhibits the breakdown of cAMP and cGMP, thereby slowing or halting their hydrolysis.

HY-161290

PDE5-IN-12	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-12 (compound 4h) is a potent **phosphodiesterase-5 (PDE-5)** inhibitor with an IC₅₀ of 22 nM. PDE5-IN-12 shows anti-proliferative effects against the aortic cell line .

HY-142660

PDE2A-IN-1	Phosphodiesterase (PDE)	Neurological Disease
PDE2A-IN-1 is a **phosphodiesterase 2A (PDE2A)** inhibitor with an IC₅₀ value of 1.3 nM.

HY-W171611

PDE-IN-3	Phosphodiesterase (PDE)	Neurological Disease
PDE-IN-3 (compound 23) is a **phosphodiesterase (PDE)** inhibitor with an IC₅₀ of 260 μM .

HY-101644A

Saterinone hydrochloride BDF 8634 hydrochloride	Phosphodiesterase (PDE)	Cardiovascular Disease
Saterinone hydrochloride is a phosphodiesterase III (PDE III) inhibitor.

HY-101644

Saterinone BDF 8634	Phosphodiesterase (PDE)	Cardiovascular Disease
Saterinone is a phosphodiesterase III (PDE III) inhibitor.

HY-119611A

Thioquinapiperifil dihydrochloride KF31327	Phosphodiesterase (PDE)	Metabolic Disease Endocrinology
Thioquinapiperifil dihydrochloride (KF31327), a potent, selective and non-competitive **phosphodiesterase-5 (PDE-5, IC₅₀** of 0.074 nM) inhibitor, is used for sexual enhancement study .

HY-U00254

L791943	Phosphodiesterase (PDE)	Neurological Disease
L791943 is a potent, selective *Phosphodiesterase-4* (PDE4) inhibitor with an IC₅₀ of 4.2 nM.

HY-124768

PDE12-IN-3	Phosphodiesterase (PDE)	Infection Inflammation/Immunology
PDE12-IN-3 is a phosphodiesterase 12 (PDE12) inhibitor with a pXC₅₀ of 7.68. Antiviral activity .

HY-101661

Win 58237	Phosphodiesterase (PDE)	Cardiovascular Disease
Win 58237 is a cyclic nucleotide **phosphodiesterase (PDE)** inhibitor, with K_i of 170 nM for PDE V, possessing vasorelaxant activity.

HY-16900

Rolipram 10+ Cited Publications (R,S)-Rolipram; (±)-Rolipram; ZK 62711	Phosphodiesterase (PDE) Bacterial HIV	Neurological Disease Cancer
Rolipram is a selective phosphodiesterases *PDE4* inhibitor with IC₅₀s of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.

HY-147990

PDE5-IN-5	Phosphodiesterase (PDE)	Cancer
PDE5-IN-5 (Compound 11) is a potent, selective **phosphodiesterase 5 (PDE5)** inhibitor with an IC₅₀ of 2.0 nM .

HY-145583

Mufemilast Hemay005	Phosphodiesterase (PDE)	Others
Mufemilast is a **phosphodiesterase 4 (PDE4)** inhibitor .

HY-106474

Meribendan	Phosphodiesterase (PDE)	Neurological Disease
Meribendan is a phosphodiesterase (PDE)-III inhibitor .

HY-119611

Thioquinapiperifil KF31327 free base	Phosphodiesterase (PDE)	Metabolic Disease Endocrinology
Thioquinapiperifil (KF31327 free base), a potent, selective and non-competitive **phosphodiesterase-5 (PDE-5, IC₅₀** of 0.074 nM) inhibitor, is used for sexual enhancement study .

HY-158237

PDE10A-IN-3	Phosphodiesterase (PDE)	Neurological Disease
PDE10A-IN-3 (Compound 8a) is an inhibitor of phosphodiesterase 10A (PDE10A). PDE10A-IN-3 can be used in schizophrenia research .

HY-124388

PDE4-IN-20	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-20 is a selective submicromolar phosphodiesterase-4 (PDE4) inhibitor with anti-TNF-α properties. PDE4-IN-20 exhibits significant biological activity in vitro and in vivo. The mechanism of action of PDE4-IN-20 is supported by molecular modeling studies, which reveal its binding mode with PDE4. PDE4-IN-20 was optimized in further conformational analysis and showed pharmacological characteristics similar to those of known PDE4 inhibitors .

HY-100927

Ro 20-1724 Ro 20-174	Phosphodiesterase (PDE)	Neurological Disease
Ro 20-1724 (Ro 20-174) is a potent inhibitor of cAMP-specific phosphodiesterase *(PDE4/PDE* IV) with a K_i** of 1930 nM. Neuroprotective effect .

HY-W011336

PDE5-IN-7	Phosphodiesterase (PDE)	Others
PDE5-IN-7 (compound 8) is a selective phosphodiesterase 5 (PDE 5) inhibitor with an IC₅₀ value of 5 nM, while an IC₅₀ of 300 nM for PDE 1 .

HY-109193

Tovinontrine IMR-687	Phosphodiesterase (PDE)	Cardiovascular Disease
Tovinontrine (IMR-687) is a highly potent and selective **phosphodiesterase-9 (PDE9)** inhibitor specifically for the treatment of sickle cell disease. IC₅₀s are 8.19 nM and 9.99 nM for PDE9A1 and PDE9A2, respectively .

HY-16900A

(R)-(-)-Rolipram 2 Publications Verification (R)-Rolipram; (-)-Rolipram	Phosphodiesterase (PDE)	Neurological Disease
(R)-(-)-Rolipram is the R-enantiomer of Rolipram. Rolipram is a selective inhibitor of phosphodiesterases *PDE4* with IC₅₀ of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.

HY-12318

IBMX Maximum Cited Publications 40 Publications Verification 3-Isobutyl-1-methylxanthine; Isobutylmethylxanthine	Phosphodiesterase (PDE)	Inflammation/Immunology
IBMX is a broad-spectrum phosphodiesterase (PDE) inhibitor, with IC₅₀s of 6.5, 26.3 and 31.7 μM for *PDE3, PDE4* and *PDE5*, respectively.

HY-14550A

PDE10-IN-5	Phosphodiesterase (PDE)	Others
PDE10-IN-5 is a phosphodiesterase 10 (PDE 10) inhibitor, can be used for researching certain central nervous system (CNS) disorders .

HY-163285

PDE3B-IN-1	Phosphodiesterase (PDE)	Metabolic Disease
PDE3B-IN-1 is a selective inhibitor for phosphodiesterase *PDE3B* with an IMAP pIC₅₀ of 6.5 and a PDE3B/A selective index >300 .

HY-100326

PDE7-IN-3	Phosphodiesterase (PDE)	Neurological Disease Inflammation/Immunology
Pde7-in-3 (example 2) is an inhibitor of the phosphodiesterase *PDE7* with potential analgesic activity. PDE7-IN-3 can be used to study inflammatory, neuropathic, visceral and nociceptive pain .

HY-18252

Avanafil 1 Publications Verification TA1790	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite	Cardiovascular Disease Endocrinology
Avanafil (TA-1790) is a potent and selective **phosphodiesterase-5 (PDE-5)** inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-122942

Moracin M 1 Publications Verification	Phosphodiesterase (PDE) Endogenous Metabolite NF-κB Autophagy	Inflammation/Immunology
Moracin M is a phenolic component that can be isolated from Mori Cortex, is a potent **phosphodiesterase-4 (PDE4)** inhibitor with IC₅₀ values of 2.9, 4.5, >40, and >100 μM for PDE4D2, PDE4B2, PDE5A1, and PDE9A2, respectively. Moracin M has anti-inflammatory activity .

HY-A0027

Fenspiride hydrochloride	Histamine Receptor Phosphodiesterase (PDE)	Inflammation/Immunology Endocrinology
Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC₅₀ values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases .

HY-A0027A

Fenspiride	Histamine Receptor Phosphodiesterase (PDE)	Inflammation/Immunology
Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC₅₀ values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases .

HY-130262

PDE1-IN-3	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE1-IN-3, compound 4 (WO2019156861), is a selective human **phosphodiesterase 1 (PDE1)** inhibitor. PDE1-IN-3 inhibits PDE4D and PDE6AB with IC₅₀ values of 23.99 μM and 10 μM, respectively .

HY-U00374

Sch59498	Phosphodiesterase (PDE)	Neurological Disease
Sch59498 is a potent inhibitor of **phosphodiesterase 1c (Pde1c)**.

HY-136350

BRD9500	Phosphodiesterase (PDE)	Cancer
BRD9500 is an orally active phosphodiesterases 3 (PDE3) inhibitor with IC₅₀s of 10 and 27 nM for *PDE3A* and *PDE3B*, respectively. Antitumor activity .

HY-18252A

Avanafil dibenzenesulfonate TA1790 dibenzenesulfonate	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite	Cardiovascular Disease Endocrinology
Avanafil (TA-1790) dibenzenesulfonate is a potent and selective **phosphodiesterase-5 (PDE-5)** inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis .

HY-18252R

Avanafil (Standard)	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite	Cardiovascular Disease Endocrinology
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-112555

PDE7-IN-2	Phosphodiesterase (PDE)	Neurological Disease
PDE7-IN-2 (compound 2) is a potent PDE7 (phosphodiesterase 7) inhibitor with IC₅₀ value of 2.1 µM. PDE7-IN-2 has the potential for the research of parkinson’s disease .

HY-B0442

Vardenafil 2 Publications Verification	Phosphodiesterase (PDE) Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Vardenafil is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0442A

Vardenafil hydrochloride 2 Publications Verification	Phosphodiesterase (PDE) Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Vardenafil hydrochloride is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0442C

Vardenafil dihydrochloride	Endogenous Metabolite Phosphodiesterase (PDE)	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Vardenafil dihydrochloride is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM respectively, while IC₅₀s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^- .

HY-117838

Phosphodiesterase 10-IN-2	Phosphodiesterase (PDE)	Neurological Disease
Phosphodiesterase 10-IN-2 (THPP-4) is an oral active **phosphodiesterase 10A (PDE10A)** inhibitor with the K_i of 4.5 nM. Phosphodiesterase 10-IN-2 can be used for study of schizophrenia .

HY-109992

LY 186126	Phosphodiesterase (PDE)	Cardiovascular Disease
LY 186126 a Indolidan analog, is a **phosphodiesterase (PDE)** inhibitor. LY 186126 binds to cardiac sarcoplasmic reticulum PDE with high affinity, with a K_d of 5.6 nM .

HY-U00186

K134 OPC33509	Phosphodiesterase (PDE)	Cardiovascular Disease
K134 is a phosphodiesterase 3 (PDE3) inhibitor. The IC₅₀s of K134 toward *PDE3A, PDE3B, PDE5, PDE2 and PDE*4 are 0.1, 0.28, 12.1, >300 and >300 µM, respectively.

HY-101826

ER21355	Phosphodiesterase (PDE)	Cancer
ER21355 is an inhibitor of **phosphodiesterase 5 (PDE5)**, used for treatment of prostatic diseases.

HY-106230A

Dasantafil SCH-446132	Phosphodiesterase (PDE)	Others
Dasantafil (SCH-446132) is a small molecule *phosphodiesterase*-5A (PDE5A) inhibitor used to in genitourinary disorders and study erectile dysfunction .

HY-147946

PDE1-IN-4	Phosphodiesterase (PDE) Calcium Channel	Inflammation/Immunology
PDE1-IN-4 (compound 2g) is a potent and selective *PDE1* (phosphodiesterase-1) inhibitor, with IC₅₀ values of 10, 145, and 354 nM for *PDE1C, PDE1A, and PDE1B, respectively. PDE1-IN-4 inhibits* myofibroblast differentiation of human lung fibroblasts induced by TGF-β1. PDE1-IN-4 shows anti-fibrosis effects through the regulation of cAMP (3′,5′-cyclic adenosine monophosphate) and cGMP (3′,5′-cyclic guanosine monophosphate). PDE1-IN-4 can be used for idiopathic pulmonary fibrosis (IPF) research .

HY-17464

Cilostazol 4 Publications Verification OPC 13013	Phosphodiesterase (PDE) Autophagy	Cardiovascular Disease Cancer
Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC₅₀ of 0.2 μM .

HY-150060

PDE4-IN-11	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-11 is an inhibitor of phosphodiesterase isoenzyme 4 (PDE4). PDE4-IN-11 displays highly effective bronchodilatory and anti-inflammatory properties, can be used for obstructive or inflammatory airway diseases research .

Cat. No.	Product Name	Type

HY-12318G

IBMX (GMP) 3-Isobutyl-1-methylxanthine (GMP); Isobutylmethylxanthine (GMP)	Fluorescent Dye
IBMX (3-Isobutyl-1-methylxanthine) (GMP) is IBMX (HY-12318) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. IBMX is a broad-spectrum phosphodiesterase (PDE) inhibitor .

Cat. No.	Product Name	Type

HY-12318G

IBMX (GMP) 3-Isobutyl-1-methylxanthine (GMP); Isobutylmethylxanthine (GMP)	Biochemical Assay Reagents
IBMX (3-Isobutyl-1-methylxanthine) (GMP) is IBMX (HY-12318) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. IBMX is a broad-spectrum phosphodiesterase (PDE) inhibitor .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks